FTC: Martin Shkreli Contempt Sought Over Pharma Ban Violations

• The FTC and seven states are seeking to hold Martin Shkreli in civil contempt for allegedly violating his lifetime pharmaceutical industry ban.
• Regulators claim Shkreli has publicly traded pharmaceutical stocks and offered investment advice since his release from prison in May 2022.
• The lifetime ban was imposed in January 2022 by U.S. District Judge Denise Cote after Shkreli was found liable for antitrust violations related to Daraprim.
• Penalties sought include forfeiture of trading profits, divestment of stock, fines, and potential jail time for future violations.
• New York Attorney General Letitia James stated that Shkreli's livestreaming of trades constitutes a violation of the law and that a court-ordered ban is not a suggestion.

The legal action against Shkreli highlights how public activities, including social media engagement and investment advice, can be leveraged as evidence in contempt proceedings.

The Federal Trade Commission (FTC), alongside attorneys general from seven states, has formally requested a New York federal judge to find Martin Shkreli in civil contempt. This action stems from allegations that the entrepreneur, known for his controversial past, has repeatedly violated a permanent injunction issued in January 2022, which imposed a lifetime pharmaceutical industry ban. Regulators contend that since his release from prison in May 2022, Shkreli has engaged in public trading of pharmaceutical stocks and offered investment advice concerning such companies, directly contravening the court's order.

These alleged violations include Shkreli publicly discussing the pharmaceutical sector and encouraging his social media followers to make investments based on his recommendations. Specifically, authorities highlight his boasts about profiting from short positions on various small pharmaceutical firms, which are particularly susceptible to significant stock price fluctuations. The FTC and its co-plaintiffs, including New York Attorney General Letitia James, assert that Shkreli's activities on platforms like YouTube, X, and Reddit are likely just a fraction of his total trading, citing his own admission that "I have some other accounts that I’[d] show you, but, like, I know feds are watching, so f[*]ck that."

In response to these alleged Shkreli antitrust injunction violation, regulators are seeking stringent penalties from Senior U.S. District Judge Denise Cote. They demand that Shkreli forfeit all profits derived from his trading activities and divest all his pharmaceutical stock holdings. Furthermore, they request a fine equivalent to his trading profits, with the possibility of additional fines or even jail time for any future non-compliance. The legal action also seeks a court order preventing Shkreli, his sister Leonora Izerne, and his significant other Chelsea Voss from destroying any evidence pertinent to past, present, or future violations of the permanent injunction. This FTC civil contempt Shkreli injunction case underscores the broad scope of enforcement for such orders.

The current FTC Martin Shkreli contempt pharma ban proceedings are rooted in a civil case from January 2022, where Shkreli was found liable for violating both federal and state antitrust statutes. This judgment followed his acquisition of Daraprim, a critical medication, and his subsequent decision to dramatically increase its price from $17.50 to $750 per pill. His actions were found to have severely restricted competition from generic drug manufacturers, thereby limiting supply and endangering patients.

As a direct consequence of these antitrust violations, US District Judge Denise Cote Shkreli imposed a comprehensive and permanent injunction. This ruling explicitly banned Shkreli for life from any form of participation in the pharmaceutical industry. This Martin Shkreli lifetime pharmaceutical industry ban was designed to prevent any future engagement that could replicate his past predatory practices.

It is important to note that these civil antitrust findings and the resulting ban are distinct from Shkreli's earlier legal troubles. He was convicted in August 2017 on securities fraud charges, which were unrelated to the Daraprim pricing controversy. The current contempt allegations specifically target his conduct following the 2022 injunction, highlighting the ongoing scrutiny of his activities within the financial and pharmaceutical spheres.

The move by the FTC and state attorneys general to pursue FTC civil contempt Shkreli injunction charges against Martin Shkreli sends a clear message regarding the enforcement of judicial orders. New York Attorney General Letitia James emphasized the gravity of the situation, stating that "A court-ordered lifetime ban isn’t a suggestion," and highlighting that Shkreli has been "livestreaming his pharmaceutical company trades for the world to see, in violation of the law." Her comments underscore the regulatory commitment to ensuring compliance with antitrust remedies.

This case is significant for demonstrating the broad interpretation of "participating in the pharmaceutical industry" under an injunction. Regulators are scrutinizing not only direct business dealings but also public activities, including social media posts and stock trades, as evidence of non-compliance. The request for forfeiture of profits, divestment of holdings, and potential jail time illustrates the severe penalties that can arise from such violations. This robust enforcement action serves as a critical reminder that individuals under similar injunctions must adhere strictly to their terms, as public conduct can be used to establish non-compliance.

The legal action against Shkreli highlights how public activities, including social media engagement and investment advice, can be leveraged as evidence in contempt proceedings. The regulators' assertion that Shkreli's online activities are "likely the tip of the iceberg" further suggests a comprehensive approach to monitoring compliance. This case reinforces the principle that court orders, especially those designed to protect public interest from monopolistic tactics, carry substantial weight and will be enforced with full legal authority.

Lawyers and compliance officers should note the broad scope of enforcement for antitrust injunctions, particularly how public activities (including social media posts and stock trades) can be used as evidence of non-compliance, leading to severe penalties like contempt charges, forfeiture of profits, and potential jail time. This case underscores the importance of advising clients under such orders about the comprehensive nature of their restrictions.

Source: Original reporting via Courthouse News Service